Ladenburg Thalmann Maintains Buy on Marinus Pharma, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Michael Higgins maintains a 'Buy' rating on Marinus Pharma (NASDAQ:MRNS), but has lowered the price target from $17 to $13.
August 11, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Marinus Pharma's price target has been lowered from $17 to $13 by Ladenburg Thalmann, though the 'Buy' rating is maintained.
The news directly pertains to Marinus Pharma as the company's price target has been lowered by Ladenburg Thalmann. However, the 'Buy' rating is maintained which indicates a positive outlook for the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100